Allele Mail Bag: Our discovery that stem cells and other cells can be non-invasively intranasally delivered to the brain.

A few words from the blog editor:  The Allele Mail Bag is a new feature we initiated here by this post on July 20, 2009.  We like to post some of the messages that our research, business development, or customer service staff receives through Allele’s published email boxes, e.g. oligo@allelebiotech.com (for ordering any product or service), iPS@allelebiotech.com, RNAi@allelebiotech.com, FP@allelebiotech.com, Vivec@allelebiotech.com (for consulting with Allele experts on each of the focus product group. FP: fluorescent proteins.  Vivec: viral vectors).  If we find your message to be suitable as a guest post on our blog, we will ask for your permission first.

In addition to any questions about any product, service, or R&D activity that Allele may provide or perform, we also encourage you to use our communication and social networking channels to help more people become aware of your own research progress.  After all, it is by the same principle of scientific information exchange through traditional channels such as publication in journals or presentation at meetings—the better we communicate the more science benefits.

Excerpt from a recent email to iPS@allelebiotech.com, with permission from Dr. Frey:

“Hi,
I am excited to tell you that along with my collaborators in Germany, especially Lusine Danielyan MD, I have discovered that stem cells and other therapeutic cells can be non-invasively delivered to the brain using the intranasal delivery method that I developed.  The first of our papers on this new discovery was just published in European Journal of Cell Biology.  I have attached a copy of this paper.  I am hopeful that this    breakthrough, that could revolutionize the stem cell industry and make stem    cell treatments practical by eliminating the need for invasive neurosurgical implantation of cells, can facilitate the development of stem cell therapies for Parkinson’s disease, Alzheimer’s disease, stroke, traumatic brain injury and many other brain disorders.

Best Regards,
—
William H. Frey II, Ph.D., Director
Alzheimer’s Research Center
Regions Hospital
640 Jackson St.
St. Paul, MN 55101
Professor of Pharmaceutics, Neurology
and Neuroscience
University of Minnesota”

Tags: Alzheimer, brain research, cutting edge research, iPS, iPS retroviral gene delivery, lentiviral iPS vectors, neurosurgical implantation, new discovery, non-invasive delivery, Parkinson's disease, stem cells, stroke